The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Levodopa for the Treatment of Parkinson's Disease
Abstract
A 62-year-old man presents with Parkinson's disease, and treatment with levodopa is recommended. Levodopa, a naturally occurring amino acid that is metabolized to dopamine in the brain, is considered the most effective drug available for Parkinson's disease. However, after several years of therapy, serious side effects, including motor fluctuations and dyskinesias, may occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Holford, N. H. G., & Sheiner, L. B. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106060-00002 · Cited by 1,143
Responses of monkey dopamine neurons during learning of behavioral reactions
Ljungberg, T., Apicella, P., & Schultz, W. (1992) · Journal of Neurophysiology · doi:10.1152/jn.1992.67.1.145 · Cited by 987
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642
Treatment of Parkinsonism With Levodopa
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 604
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
Rapid Communication: Oxidative Stress Induces Apoptosis in Embryonic Cortical Neurons
Ratan, R. R., Murphy, T. H., & Baraban, J. M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010376.x · Cited by 584
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Dementia and survival in Parkinson disease: A 12-year population study
Buter, T. C., van den Hout, A., Matthews, F. E., Larsen, J. P., Brayne, C., & Aarsland, D. (2008) · Neurology · doi:10.1212/01.wnl.0000306632.43729.24 · Cited by 451
Young onset Parkinson's disease
Quinn, N., Critchley, P., & Marsden, C. D. (1987) · Movement Disorders · doi:10.1002/mds.870020201 · Cited by 443
(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418
Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376
A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease
Hughes, T. A., Ross, H. F., Musa, S., Bhattacherjee, S., Nathan, R. N., Mindham, R. H. S., & Spokes, E. G. S. (2000) · Neurology · doi:10.1212/wnl.54.8.1596 · Cited by 372
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citationKINETICS OF COMPETITIVE INHIBITION OF NEUTRAL AMINO ACID TRANSPORT ACROSS THE BLOOD‐BRAIN BARRIER
Pardridge, W. M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb07714.x · Cited by 367
Levodopa‐induced dyskinesia: Review, observations, and speculations
Nutt, M. (1990) · Neurology · doi:10.1212/wnl.40.2.340 · Cited by 358
Nutl, J. G., & Fellman, J. H. (1984) · Clinical Neuropharmacology · doi:10.1097/00002826-198403000-00002 · Cited by 356
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality
Schrag, A., Ben‐Shlomo, Y., Brown, R., David Marsden, C., & Quinn, N. (1998) · Movement Disorders · doi:10.1002/mds.870130605 · Cited by 311
The response to levodopa in parkinson's disease: Imposing pharmacological law and order
Nutt, J. G., & Holford, N. H. G. (1996) · Annals of Neurology · doi:10.1002/ana.410390504 · Cited by 299
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
Chase, T. N., & Oh, J. D. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00018-5 · Cited by 251
Relations between movement and single cell discharge in the substantia nigra of the behaving monkey
DeLong, M., Crutcher, M., & Georgopoulos, A. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01599.1983 · Cited by 247
De La Fuente‐Fernández, R., Lu, J., Sossi, V., Jivan, S., Schulzer, M., Holden, J. E., Lee, C. S., Ruth, T. J., Calne, D. B., & Stoessl, A. J. (2001) · Annals of Neurology · doi:10.1002/ana.65 · Cited by 247
Stacy, M., Bowron, A., Guttman, M., Hauser, R., Hughes, K., Larsen, J. P., LeWitt, P., Oertel, W., Quinn, N., Sethi, K., et al. (2005) · Movement Disorders · doi:10.1002/mds.20383 · Cited by 246
Self-citationSuchowersky, O., Gronseth, G., Perlmutter, J., Reich, S., Zesiewicz, T., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000206363.57955.1b · Cited by 237
Murer, M. G., Dziewczapolski, G., Menalled, L. B., García, M. C., Agid, Y., Gershanik, O., & Raisman‐Vozari, R. (1998) · Annals of Neurology · doi:10.1002/ana.410430504 · Cited by 232
SYNTHETIC AMINO ACIDS AND THE NATURE OF l‐DOPA TRANSPORT AT THE BLOOD‐BRAIN BARRIER
Wade, L. A., & Katzman, R. (1975) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1975.tb04415.x · Cited by 211
Koller, W. C., Hutton, J. T., Tolosa, E., Capilldeo, R., & the Carbidopa/Levodopa Study Group (1999) · Neurology · doi:10.1212/wnl.53.5.1012 · Cited by 200
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations
Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E., Sancesario, G., Bernardi, G., Bergamaschi, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000221672.01272.ba · Cited by 199
Parkinson’s disease and anxiety
Walsh, K., & Bennett, G. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.904.89 · Cited by 193
Management of Parkinson's disease: An evidence-based review
Lang, A. E., & Lees, A. (2002) · Movement Disorders · doi:10.1002/mds.5554 · Cited by 184
Functional neuroanatomy of the basal ganglia in Parkinson's disease.
Wichmann, T., & DeLong, M. R. (2003) · PubMed · Cited by 169
Update on the genetics of Parkinson's disease
Gasser, T. (2007) · Movement Disorders · doi:10.1002/mds.21676 · Cited by 168
Nonmotor complications in Parkinson's disease
Adler, C. H. (2005) · Movement Disorders · doi:10.1002/mds.20460 · Cited by 165
Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Obeso, J. A., Grandas, F., Vaamonde, J., Luquín, M. R., Artieda, J., Lera, G., Rodriguez, M. E., & Martínez‐Lage, J. M. (1989) · PubMed · Cited by 163
Slowing Parkinson’s disease progression: Recent dopamine agonist trials
Ahlskog, J. E. (2003) · Neurology · doi:10.1212/01.wnl.0000044047.58984.2f · Cited by 161
Rater-blinded, Prospective Comparison
Merims, D., Balas, M., Peretz, C., Shabtai, H., & Giladi, N. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000236769.31279.19 · Cited by 156
Waters, C., Sethi, K. D., Hauser, R. A., Molho, E., & Bertoni, J. M. (2004) · Movement Disorders · doi:10.1002/mds.20036 · Cited by 153
The cytotoxicity of dopamine may be an artefact of cell culture
Clement, M., Long, L. H., Ramalingam, J. K., & Halliwell, B. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00802.x · Cited by 145
Motor fluctuations and dyskinesia in Parkinson's disease
Nutt, J. G. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00024-4 · Cited by 141
The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease
Khor, S. P., & Hsu, A. (2007) · Current Clinical Pharmacology · doi:10.2174/157488407781668802 · Cited by 135
Goetz, C. G., Leurgans, S. E., & Raman, R. (2002) · Movement Disorders · doi:10.1002/mds.10024 · Cited by 135
Influence of Motor Symptoms upon the Quality of Life of Patients with Parkinson’s Disease
Gómez‐Esteban, J. C., Zarranz, J. J., Lezcano, E., Tijero, B., Luna, A., Velasco, F., Rouco, I., & Garamendi, Í. (2007) · European Neurology · doi:10.1159/000098468 · Cited by 134
Evolution of the response to levodopa during the first 4 years of therapy
Nutt, J. G., Carter, J. H., Lea, E. S., & Sexton, G. J. (2002) · Annals of Neurology · doi:10.1002/ana.10189 · Cited by 130
Westin, J. E., Andersson, M., Lundblad, M., & Cenci, M. A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01743.x · Cited by 129
Clinical–Pathological study of levodopa complications
Rajput, A. H., Fenton, M. E., Birdi, S., Macaulay, R. J. B., George, D. H., Rozdilsky, B., Ang, L. C., Senthilselvan, A., & Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10031 · Cited by 127
Kaakkola, S., Teräväinen, H., Ahtila, S., Rita, H., & Gordin, A. (1994) · Neurology · doi:10.1212/wnl.44.1.77 · Cited by 125
Orthostatic Hypotension in Patients with Parkinson??s Disease: Pathophysiology and Management
Sénard, J., Brefel‐Courbon, C., Rascol, O., & Montastruc, J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118070-00003 · Cited by 124
Neurotrophic Effects of l ‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte Cocultures
Mena, M. A., Davila, V., & Sulzer, D. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041398.x · Cited by 124
Dopamine miracle: From brain homogenate to dopamine replacement
Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10115 · Cited by 122
Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy?
Postuma, R. B., & Lang, A. E. (2004) · Neurology · doi:10.1212/01.wnl.0000137886.74175.5a · Cited by 112
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2005) · Movement Disorders · doi:10.1002/mds.20421 · Cited by 112
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Nutt, J. G. (2006) · Movement Disorders · doi:10.1002/mds.21060 · Cited by 109
Zeng, B. ‐., Pearce, R. K. B., MacKenzie, G. M., & Jenner, P. G. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00988.x · Cited by 107
Short‐ and long‐duration responses to levodopa during the first year of levodopa therapy
Nutt, J. G., Carter, J. H., Houten, L. V., & Woodward, W. R. (1997) · Annals of Neurology · doi:10.1002/ana.410420311 · Cited by 103
Medicine‐taking behavior: Implications of suboptimal compliance in Parkinson's disease
Grosset, K. A., Reid, J. L., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20525 · Cited by 98
Ahlskog, J. E. (2004) · Movement Disorders · doi:10.1002/mds.20362 · Cited by 96
Carter, J. H., Nutt, J. G., Woodward, W. R., Hatcher, L. F., & Trotman, T. L. (1989) · Neurology · doi:10.1212/wnl.39.4.552 · Cited by 95
Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease
Potenza, M. N., Voon, V., & Weintraub, D. A. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0680 · Cited by 94
Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease
Zappia, M., Crescibene, L., Arabia, G., Nicoletti, G., Bagalà, A., Bastone, L., Caracciolo, M., Bonavita, S., Costanzo, A. D., Scornaienchi, M., et al. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00004 · Cited by 91
Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_12 · Cited by 81
Serotonergic dysfunction in depression associated with Parkinson's disease
McCance‐Katz, E. F., MAREK, K. L., & Price, L. H. (1992) · Neurology · doi:10.1212/wnl.42.9.1813 · Cited by 80
l-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system
Misu, Y., Kitahama, K., & Goshima, Y. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00325-x · Cited by 75
Brooks, D. J., Agid, Y., Eggert, K. M., Widner, H., Østergaard, K., & Holopainen, A. (2005) · European Neurology · doi:10.1159/000086479 · Cited by 66
Reappraisal of Temporary Levodopa Withdrawal (Drug Holiday) in Parkinson's Disease
Mayeux, R. P., Stern, Y., Mulvey, K. P., & COTE, L. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509193131204 · Cited by 62
Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation
Chan, P. L. S., Nutt, J. G., & Holford, N. H. G. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9202-3 · Cited by 61
Protection Against Parkinson’s Disease Progression: Clinical Experience
LeWitt, P. A., & Taylor, D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.007 · Cited by 61
Self-citationYahr, M. D., & Duvoisin, R. C. (1972) · New England Journal of Medicine · doi:10.1056/nejm197207062870105 · Cited by 56
Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature
Zanetti, R., Loria, D., & Rosso, S. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000215043.61306.d7 · Cited by 56
Relationship of aging to Parkinson's disease.
Koller, W. C., O'Hara, R., Weiner, W. J., Lang, A. E., Nutt, J. G., Agid, Y., Bonnet, A. M., & Jankovic, J. J. (1987) · PubMed · Cited by 48
Early Morning Off-Medication Dyskinesias, Dystonia, and Choreic Subtypes
Cubo, E., Graciès, J., Benabou, R., Olanow, C. W., Raman, R., Leurgans, S. E., & Goetz, C. G. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1379 · Cited by 41
Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease
Hashimoto, T., Tokuda, T., Hanyu, N., Tabata, K., & Yanagisawa, N. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00119-0 · Cited by 35
Djaldetti, R., Inzelberg, R., Giladi, N., Korczyn, A. D., Peretz-Aharon, Y., Rabey, M. J., Herishano, Y., Honigman, S., Badarny, S., & Melamed, E. (2002) · Movement Disorders · doi:10.1002/mds.10075 · Cited by 32
Cited by
Direct and indirect pathways of basal ganglia: a critical reappraisal
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3743 · Cited by 828
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationMollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
LeWitt, P. A. (2015) · Movement Disorders · doi:10.1002/mds.26082 · Cited by 391
Self-citationMa, K., Xiong, N., Shen, Y., Han, C., Liu, L., Zhang, G., Wang, L., Guo, S., Guo, X., Xia, Y., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00001 · Cited by 379
Metadata
- Authors
- LeWitt, P. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2468-2476
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993408885
- Cited by
- 312
- References
- 84
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.